HER2、EGFR、ER、PR在乳腺癌中的表达及其临床意义

Expressions of HER2,EGFR,ER and PR in breast cancer and their clinical implications

目的探讨人表皮生长因子受体2(HER2)、表皮生长因子受体(EGFR)、雌激素受体(ER)、孕激素受体(PR)在乳腺癌中的表达及其临床意义。方法用免疫组化方法检测182例乳腺浸润性导管癌和小叶癌患者HER2、EGFR、ER、PR的表达情况,并进行比较。结果HER2、EGFR、ER、PR表达阳性率分别为36.8%、42.3%、53.8%、50.5%。HER2的表达与EGFR呈正相关性(P<0.05),与ER和PR呈负相关(P<0.05)。HER2、EGFR、ER、PR表达与乳腺癌的组织学分级相关(P<0.05)。HER2、EGFR、ER表达与淋巴结转移相关(P<0.05),HER2、EGFR、ER、PR与乳腺癌的病理学类型、患者年龄及肿瘤大小无关(P>0.05)。结论乳腺癌中HER2、EGFR表达提示患者预后不良,ER、PR表达提示患者预后良好,HER2、EGFR、ER、PR是判断乳腺癌预后的有效指标,并可作为临床选择内分泌治疗或基因靶向治疗的指南。

Objective To detect the expressions of HER2、EGFR、ER and PR in breast cancer and discuss their clinical implications.Methods The expressions of HER2,EGFR,ER and PR were measured immunohistochemically in 182 patients with breast cancer.Results The positive expression rates of HER2,EGFR,ER and PR were 36.8%,42.3%,53.8% and 50.5% respectively in the breast cancer patients.The expression of HER2 was correlated with EGFR,but inversely correlated with ER and PR.The expressions of HER2 and EGFR,ER,PR were correlate...